Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX

Table 2 Changes in peripheral blood parameters at baseline and post-treatment, median (range)

	Baseline	Post-treatment	P value
Laboratory examination
Neutrophil count (× 109/L)	3.25 (2.70, 4.22)	3.21 (2.60, 4.22)	0.653
Lymphocyte count (× 109/L)	1.44 (1.14, 1.91)	1.18 (0.88, 1.68)	0.000
Monocyte count (× 109/L)	0.39 (0.29, 0.46)	0.51 (0.42, 0.65)	0.000
Blood platelet count (× 109/L)	245.00 (204.00, 315.00)	168.00 (111.00, 202.00)	0.000
T lymphocyte subsets
CD3+ T lymphocytes (%)	72.00 (64.00, 80.40)	80.50 (72.60, 84.10)	0.000
CD4+ T lymphocytes (%)	41.60 (33.50, 46.10)	41.30 (34.90, 50.50)	0.171
CD8+ T lymphocytes (%)	28.70 (19.10, 35.80)	32.70 (21.60, 41.50)	0.002
Inflammatory indicators
NLR	2.35 (1.79, 3.17)	2.68 (2.11, 4.02)	0.070
MLR	0.28 (0.21, 0.35)	0.43 (0.32, 0.64)	0.000
PLR	182.05 (131.82, 207.24)	121.05 (92.19, 211.97)	0.005

NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; MLR: Monocyte-to-lymphocyte ratio.